425 related articles for article (PubMed ID: 31101672)
1. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection.
Kose N; Fox JM; Sapparapu G; Bombardi R; Tennekoon RN; de Silva AD; Elbashir SM; Theisen MA; Humphris-Narayanan E; Ciaramella G; Himansu S; Diamond MS; Crowe JE
Sci Immunol; 2019 May; 4(35):. PubMed ID: 31101672
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus.
August A; Attarwala HZ; Himansu S; Kalidindi S; Lu S; Pajon R; Han S; Lecerf JM; Tomassini JE; Hard M; Ptaszek LM; Crowe JE; Zaks T
Nat Med; 2021 Dec; 27(12):2224-2233. PubMed ID: 34887572
[TBL] [Abstract][Full Text] [Related]
3. A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.
Lam S; Nyo M; Phuektes P; Yew CW; Tan YJ; Chu JJ
MAbs; 2015; 7(6):1178-94. PubMed ID: 26305993
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus.
Clayton AM
J Infect Dis; 2016 Dec; 214(suppl 5):S506-S509. PubMed ID: 27920182
[TBL] [Abstract][Full Text] [Related]
5. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes.
Pal P; Fox JM; Hawman DW; Huang YJ; Messaoudi I; Kreklywich C; Denton M; Legasse AW; Smith PP; Johnson S; Axthelm MK; Vanlandingham DL; Streblow DN; Higgs S; Morrison TE; Diamond MS
J Virol; 2014 Aug; 88(15):8213-26. PubMed ID: 24829346
[TBL] [Abstract][Full Text] [Related]
6. Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.
Smith SA; Silva LA; Fox JM; Flyak AI; Kose N; Sapparapu G; Khomandiak S; Ashbrook AW; Kahle KM; Fong RH; Swayne S; Doranz BJ; McGee CE; Heise MT; Pal P; Brien JD; Austin SK; Diamond MS; Dermody TS; Crowe JE
Cell Host Microbe; 2015 Jul; 18(1):86-95. PubMed ID: 26159721
[TBL] [Abstract][Full Text] [Related]
7. Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.
Tumkosit U; Siripanyaphinyo U; Takeda N; Tsuji M; Maeda Y; Ruchusatsawat K; Shioda T; Mizushima H; Chetanachan P; Wongjaroen P; Matsuura Y; Tatsumi M; Tanaka A
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699087
[TBL] [Abstract][Full Text] [Related]
8. Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy.
Fong RH; Banik SS; Mattia K; Barnes T; Tucker D; Liss N; Lu K; Selvarajah S; Srinivasan S; Mabila M; Miller A; Muench MO; Michault A; Rucker JB; Paes C; Simmons G; Kahle KM; Doranz BJ
J Virol; 2014 Dec; 88(24):14364-79. PubMed ID: 25275138
[TBL] [Abstract][Full Text] [Related]
9. Antibody-mediated enhancement aggravates chikungunya virus infection and disease severity.
Lum FM; Couderc T; Chia BS; Ong RY; Her Z; Chow A; Leo YS; Kam YW; Rénia L; Lecuit M; Ng LFP
Sci Rep; 2018 Jan; 8(1):1860. PubMed ID: 29382880
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques.
Broeckel R; Fox JM; Haese N; Kreklywich CN; Sukulpovi-Petty S; Legasse A; Smith PP; Denton M; Corvey C; Krishnan S; Colgin LMA; Ducore RM; Lewis AD; Axthelm MK; Mandron M; Cortez P; Rothblatt J; Rao E; Focken I; Carter K; Sapparapau G; Crowe JE; Diamond MS; Streblow DN
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005637. PubMed ID: 28628616
[TBL] [Abstract][Full Text] [Related]
11. Chikungunya-specific IgG and neutralizing antibody responses in natural infection of Chikungunya virus in children from India.
Verma A; Nayak K; Chandele A; Singla M; Ratageri VH; Lodha R; Kabra SK; Murali-Krishna K; Ray P
Arch Virol; 2021 Jul; 166(7):1913-1920. PubMed ID: 33907861
[TBL] [Abstract][Full Text] [Related]
12. Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins.
Quiroz JA; Malonis RJ; Thackray LB; Cohen CA; Pallesen J; Jangra RK; Brown RS; Hofmann D; Holtsberg FW; Shulenin S; Nyakatura EK; Durnell LA; Rayannavar V; Daily JP; Ward AB; Aman MJ; Dye JM; Chandran K; Diamond MS; Kielian M; Lai JR
PLoS Pathog; 2019 Nov; 15(11):e1008061. PubMed ID: 31697791
[TBL] [Abstract][Full Text] [Related]
13. Clearance of Chikungunya Virus Infection in Lymphoid Tissues Is Promoted by Treatment with an Agonistic Anti-CD137 Antibody.
Hong JP; McCarthy MK; Davenport BJ; Morrison TE; Diamond MS
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578287
[TBL] [Abstract][Full Text] [Related]
14. Unique epitopes recognized by antibodies induced in Chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development.
Kam YW; Lee WW; Simarmata D; Le Grand R; Tolou H; Merits A; Roques P; Ng LF
PLoS One; 2014; 9(4):e95647. PubMed ID: 24755730
[TBL] [Abstract][Full Text] [Related]
15. Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus.
Pal P; Dowd KA; Brien JD; Edeling MA; Gorlatov S; Johnson S; Lee I; Akahata W; Nabel GJ; Richter MK; Smit JM; Fremont DH; Pierson TC; Heise MT; Diamond MS
PLoS Pathog; 2013; 9(4):e1003312. PubMed ID: 23637602
[TBL] [Abstract][Full Text] [Related]
16. Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose.
Abeyratne E; Tharmarajah K; Freitas JR; Mostafavi H; Mahalingam S; Zaid A; Zaman M; Taylor A
Front Immunol; 2020; 11():304. PubMed ID: 32194557
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of Chikungunya virus inhibition by monoclonal antibodies.
Zhou QF; Fox JM; Earnest JT; Ng TS; Kim AS; Fibriansah G; Kostyuchenko VA; Shi J; Shu B; Diamond MS; Lok SM
Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27637-27645. PubMed ID: 33087569
[TBL] [Abstract][Full Text] [Related]
18. Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence.
Hawman DW; Fox JM; Ashbrook AW; May NA; Schroeder KMS; Torres RM; Crowe JE; Dermody TS; Diamond MS; Morrison TE
Cell Rep; 2016 Aug; 16(5):1326-1338. PubMed ID: 27452455
[TBL] [Abstract][Full Text] [Related]
19. Chikungunya Virus Fidelity Variants Exhibit Differential Attenuation and Population Diversity in Cell Culture and Adult Mice.
Riemersma KK; Steiner C; Singapuri A; Coffey LL
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429348
[TBL] [Abstract][Full Text] [Related]
20. Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus-specific neutralizing antibody response.
Her Z; Teng TS; Tan JJ; Teo TH; Kam YW; Lum FM; Lee WW; Gabriel C; Melchiotti R; Andiappan AK; Lulla V; Lulla A; Win MK; Chow A; Biswas SK; Leo YS; Lecuit M; Merits A; Rénia L; Ng LF
EMBO Mol Med; 2015 Jan; 7(1):24-41. PubMed ID: 25452586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
